Company Encyclopedia
View More
name
Ardelyx
ARDX.US
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc.
1.902 T
ARDX.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking96/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-36.18%E
    • Profit Margin-14.20%D
    • Gross Margin80.02%A
  • Growth ScoreA
    • Revenue YoY58.12%A
    • Net Profit YoY22.09%B
    • Total Assets YoY32.16%A
    • Net Assets YoY-2.54%D
  • Cash ScoreC
    • Cash Flow Margin-704.25%E
    • OCF YoY58.12%A
  • Operating ScoreA
    • Turnover0.93A
  • Debt ScoreD
    • Gearing Ratio68.27%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ardelyx Executives Sell Shares to Cover Taxes

    Ardelyx executives Joseph James Reilly and Eric Duane Foster sold shares to cover taxes on vested restricted stock units. Reilly sold 11,086 shares for $61,382, retaining 108,914 shares. Foster sold 5,814 shares for $32,191, retaining 295,684 shares. Both transactions occurred on November 21, 2025, at $5.5369 per share.

    TradingView·
    US
    ARDX
    +5.25%
    TradingView·
    US
    ARDX
    +5.25%

    CEO Raab Surrenders 46,887 Of Ardelyx Inc [ARDX]

    CEO Raab Michael of Ardelyx Inc surrendered 46,887 shares back to the company to cover option exercise costs and/or tax liabilities, as disclosed in a Form 4 filed with the SEC. The transaction, dated November 21, 2025, was valued at $259,609, leaving Raab with 1,480,727 shares. This action is part of insider trading activities.

    Reuters·
    US
    ARDX
    +5.25%
    Reuters·
    US
    ARDX
    +5.25%

    Officer Foster Files To Sell 5,502 Of Ardelyx Inc [ARDX]

    Officer Eric Duane Foster of Ardelyx Inc filed a Form 144 with the SEC to sell 5,502 restricted shares on November 20, 2025. The sale will be conducted through Morgan Stanley Smith Barney LLC. Filing Form 144 is a prerequisite for selling restricted stock, allowing the owner to sell within 90 days of filing.

    Reuters·
    US
    ARDX
    +5.25%
    Reuters·
    US
    ARDX
    +5.25%

    Ardelyx (ARDX): Evaluating Valuation After Upward Guidance Following Strong IBSRELA Sales Growth

    Ardelyx (ARDX) has raised its 2025 revenue guidance for IBSRELA following a 92% year-over-year sales growth, leading to a 15.5% one-month share price increase. The stock is currently trading at $5.81, significantly below its fair value of $11.73, indicating it is undervalued. Despite strong growth, risks include reliance on a narrow product range and Medicare reimbursement uncertainties. Investors are encouraged to explore Ardelyx's long-term growth potential and other investment opportunities.

    Simplywall·
    US
    ARDX
    +5.25%
    Simplywall·
    US
    ARDX
    +5.25%

    BTIG Maintains a Buy on Ardelyx, Inc (ARDX)

    ​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earlier on November 4, Allison Bratzel from Piper Sandler raised the firm’s price target on the stock from […]

    MSN·
    US
    ARDX
    +5.25%
    MSN·
    US
    ARDX
    +5.25%
    © 2025 Longbridge｜Disclaimer